SciSparc Ltd.

0.52
0.01 (0.97%)
At close: Jan 28, 2025, 1:51 PM

Company Description

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules.

Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.

The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form.

It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation.

The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.

SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

SciSparc Ltd.
SciSparc Ltd. logo
Country IL
IPO Date Aug 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 3
CEO Itschak Shrem

Contact Details

Address:
Tower A
Tel Aviv,
IL
Website https://scisparc.com

Stock Details

Ticker Symbol SPRC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001611746
CUSIP Number M82618105
ISIN Number IL0010951403
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Adi Zuloff-Shani Ph.D. Chief Technologies Officer
Itschak Shrem President & Director

Latest SEC Filings

Date Type Title
Jan 21, 2025 POS AM Filing
Jan 15, 2025 6-K Filing
Jan 07, 2025 6-K Filing
Dec 31, 2024 F-4/A [Amend] Filing
Dec 31, 2024 6-K Filing
Dec 26, 2024 425 Filing
Dec 26, 2024 6-K Filing
Dec 17, 2024 6-K Filing
Nov 29, 2024 425 Filing
Nov 29, 2024 6-K Filing